Coming soon: First-in-human study of gene-modifying drug for hypercholesterolemia
Cardiovascular Business
|
January 23, 2026
X min read
Cardiovascular Business
|
January 23, 2026
Share on Social
More like this
Media
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
September 2, 2026
Read Now
Press
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
September 2, 2026
Read Now
